Nurtec^mODT (rimegepant)

orally disintegrating tablets 75 mg

NURTEC[™] ODT (rimegepant) is the first and only calcitonin generelated peptide (CGRP) receptor antagonist available in an orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

The Benefits of NURTEC ODT

More than 74 percent of patients are not completely satisfied with their acute treatments.¹ As migraine can strike without warning, NURTEC ODT is a convenient, discreet treatment, taken anytime, anywhere that can start to work in minutes.²









Treats a root cause of migraine in a single dose with **rapid and sustained benefits**² Ease of use with orally disintegrating tablet

Pain relief and return to normal function at **one hour in many patients**²

The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo.)²

Select Important Safety Information

Hypersensitivity reactions, including dyspnea and rash, have occurred with NURTEC ODT in clinical studies. Hypersensitivity reactions with dyspnea and severe rash, including delayed serious hypersensitivity days after administration, occurred in less than 1% of patients taking NURTEC ODT in clinical studies.

Why NURTEC ODT is Different

ORALLY DISINTEGRATING TABLET

- Disperses in seconds in the mouth
- No water required
- Take anytime, anywhere discreetly

CARDIOVASCULAR SYSTEM

NURTEC ODT may offer an alternative treatment option, particularly for patients who experience inadequate efficacy, poor tolerability, or have a contraindication to currently available therapies.³

Efficacy and Safety

In a multicenter, randomized, placebo controlled Phase 3 study, NURTEC ODT **achieved statistical significance** on the co-primary endpoints of **pain freedom** and **freedom from most bothersome symptom at two hours.**²



Pain relief and return to normal function at **one hour in many patients**²

ONE DOSE



86% of patients **did not require rescue medication** within 24 hours post dose versus 71% for placebo treated patients ²



Sustained relief for two days⁴

- Pain freedom and freedom from most bothersome symptom
- ✓ Pain relief
- Return to normal function

 Minimal side effects
Nausea occurred in 2% of patients as compared to 0.4% of patients on placebo

INDICATION

What is NURTEC[™] ODT (rimegepant)?

NURTEC ODT orally disintegrating tablets is a prescription medicine for the acute treatment of migraine for attacks with or without aura in adults. NURTEC ODT is not used as a preventive treatment of migraine. It is not known if NURTEC ODT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take NURTEC ODT if you are allergic to NURTEC ODT (rimegepant) or any of its ingredients.

Before you take NURTEC ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:

- have liver problems
- have kidney problems
- are pregnant or plan to become pregnant,
- breastfeeding or plan to breastfeed.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NURTEC ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take NURTEC ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with NURTEC ODT.

The most common side effect of NURTEC ODT was nausea (2% of patients). This is not the only possible side effect of NURTEC ODT. Tell your HCP if you have any side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit <u>www.fda.gov/medwatch</u> or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4NURTEC.

Please click here for full <u>Prescribing Information</u> and <u>Patient Information</u>.

For more information and full prescribing information, visit www.biohaven.com.

NURTEC is a trademark of Biohaven Pharmaceutical Holding Company Ltd.

REFERENCES

1. Based on a December 23, 2019-January 17, 2020 U.S. online survey completed by 1076 adults with migraine. Respondents were recruited from the National Headache Foundation membership list. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *The Lancet* 2019;394(10200):737-745. 3. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a doubleblind, randomized, placebo controlled, dose-ranging trial. *Cephalalgia* 2014;34(2):114-25. 4. NURTEC ODT [prescribing information]. New Haven, CT. Biohaven Pharmaceuticals, Inc.